Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Phase Ⅰ Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of GT20029 Gel and Solution for Single and Multi Dose External Administration in Healthy Subjects

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase Ⅰ Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of GT20029 Gel and Solution for Single and Multi Dose External Administration in Healthy Subjects

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GT 20029 (Primary)
  • Indications Acne vulgaris; Alopecia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Suzhou Kintor Pharmaceuticals

    • Most Recent Events

    • 28 Aug 2023 According to a Kintor Pharmaceutical Limited media release, the study will be presented at EADV 2023
    • 10 Feb 2023 According to a Kintor Pharmaceutical Limited media release, the study demonsrtated the good safety and tolerability in MAD of GT20029.
    • 09 Aug 2022 According to a Kintor Pharmaceutical Limited media release, leading principal investigators (leading PIs) of the trial are Professor Zhang Jing and Associate Professor Wu Xiaojie from Huashan Hospital affiliated to Fudan University.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top